仅差一个氨基酸的抗体对活化蛋白C多效功能的差异调节
本研究以靶向活化蛋白C(APC)非活性位点的抗体TPP-26870为基础,在其互补决定区引入单氨基酸突变,筛选出21个亲和力改善的变体。功能实验显示APC多效功能对表位-互补决定区相互作用高度敏感,单氨基酸突变即可对APC各功能活性产生不同的拮抗或激动效应,包括延长体外APC血浆半衰期、增强对凝血活性的抑制及激动性增强组蛋白H3切割,而对蛋白酶激活受体1切割影响较小。
要点
- 在TPP-26870互补决定区引入单氨基酸突变,筛选出21个亲和力改善的变体。
- 单氨基酸突变即可对APC各功能活性产生不同的拮抗或激动效应。
- 变体可延长体外APC血浆半衰期并增强对凝血活性的抑制。
核心结论
- APC对非活性位点靶向高度敏感,可导致其多效酶活性谱出现不可预测的变化。
- 研究证明可对APC功能进行改造,以推进APC靶向抗体作为创伤出血、血友病、缺血和脓毒症等疾病治疗药物的潜在开发。
研究设计与样本
- 以靶向APC非活性位点的抗体TPP-26870为基础,在其互补决定区引入单氨基酸突变,筛选变体并进行功能实验。
主要发现
- 筛选出21个亲和力常数改善的变体。
- 与TPP-26870相比,单氨基酸突变变体可延长体外APC血浆半衰期、增强对凝血活性的抑制、激动性增强组蛋白H3切割,而对蛋白酶激活受体1切割影响较小。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activated protein C (APC) is a pleiotropic plasma protease with diverse functions derived from its anticoagulant, anti-inflammatory, and cytoprotective activities. The selective uncoupling and/or modulation of these APC activities by antibodies may have therapeutic benefit in diseases such as traumatic bleeding, hemophilia, sepsis, and ischemia. TPP-26870 is an antibody that targets a nonactive site of APC for the selective modulation of APC activities. To optimize the potency of TPP-26870, variants with single amino acid mutation in the complementarity-determining regions (CDRs) were screened, and 21 variants with improved affinity constant were identified. Interestingly, the affinity maturation of TPP-26870 did not merely generate a panel of variants with higher potency in functional assays. Functional data demonstrated that the pleiotropic functions of APC were very sensitive to epitope-CDR interactions. Single amino acid mutations within the CDRs of TPP-26870 were sufficient to elicit divergent antagonistic and agonistic effects on the various APC functional activities. These include prolonged in vitro APC plasma half-life, increased inhibition of anticoagulant activity, and agonistic enhancement of histone H3 cleavage, while having less impact on protease-activated receptor 1 cleavage, compared with TPP-26870. This study illustrates that APC is highly sensitive to non-active site targeting that can lead to unpredictable changes in its activity profile of this pleiotropic enzyme. Furthermore, this study demonstrates the ability to modify APC functions to advance the potential development of APC-targeted antibodies as therapeutics for the treatment of diseases including trauma bleeding, hemophilia, ischemia, and sepsis.
引用
- Sim DS, Shukla M, Mallari CR, et al. Divergent modulation of activated protein C pleiotropic functions by antibodies that differ by a single amino acid. Blood Adv. 2025. PMID: 39471469. doi:10.1182/bloodadvances.2024013584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。